Skip to main content
Arthritis Research & Therapy logoLink to Arthritis Research & Therapy
. 2025 Jun 19;27:127. doi: 10.1186/s13075-025-03587-8

Global burden and trends of musculoskeletal disorders in postmenopausal elderly women: a 1990–2021 analysis with projections to 2045

Jianye Tan 1,2,3,#, Zhenglin Zhu 1,2,3,#, Xingkuan Wang 1,2,3,#, Bingsheng Yang 4, Senrui Liu 1,2,3, Meiling Shi 5, Yujia Luo 1,2,3, Chengcheng Du 1,2,3, Yinsong Sun 1,2,3, Junyi Liao 1,2,3,✉, Yiting Lei 1,2,3,6,✉, Wei Huang 1,2,3,✉
PMCID: PMC12178034  PMID: 40537855

Abstract

Background

The global burden and trend of musculoskeletal disorders (MSDs) in postmenopausal women (PMW) remain unclear.

Methods

Using the Global Burden of Disease (GBD) 2021 data, this study assessed the prevalence and disability-adjusted life years (DALYs) for rheumatoid arthritis (RA), osteoarthritis (OA), low back pain (LBP), neck pain (NP), gout, and other musculoskeletal conditions (OMSKDs) from 1990 to 2021. Bayesian Age-Period-Cohort (BAPC) models projected trends to 2045. Health inequalities were analyzed using the Slope Index of Inequality (SII) and the Concentration Index, with decomposition methods identifying the drivers of burden changes.

Results

From 1990 to 2021, the age-standardized prevalence and DALYs rates have significantly increased among PMW, with OA and LBP being the primary contributors to this burden. These increases were primarily driven by population growth. Specifically, RA, OA, and gout accounted for more than 50% of the total burden in women across all age groups, with RA burden being 1.2 times higher than that in premenopausal women, OA 3.1 times higher, and gout 2.9 times higher. Notably, in PMW, the burden of gout was 74%. The burden of gout is strongly correlated with the Socio-Demographic Index (SDI), particularly in high-income regions, such as North America, where the United States exhibits the highest DALYs rates. Furthermore, projections indicate that by 2045, the global burden of MSDs could double, with OA potentially affecting nearly 50% of the PMW.

Conclusion

From 1990 to 2021, the global burden of MSDs among PMW has risen significantly, with notable regional disparities underscoring the critical need for tailored preventive strategies to alleviate the worldwide impact of these conditions.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13075-025-03587-8.

Keywords: Musculoskeletal disease, Estrogen, Postmenopausal women, Osteoarthritis, Low back pain

Introduction

MSDs encompass a range of conditions affecting the muscles, bones, joints, and related support structures, including gout, OA, RA, LBP, NP and OMSKDs [1, 2, 3]. Approximately 1.71 billion individuals worldwide are affected by MSDs, with numbers steadily rising, consequently driving up global treatment costs every year [4]. For instance, in Canada, annual spending on arthritis is approximately 24 billion dollars, projected to increase to 49 billion by 2031, reaching as high as 140 billion dollars annually in the United States [5, 6]. As the patient population grows, the costs associated with treatment, care, and social security for these diseases are also escalating significantly, placing immense pressure on healthcare and social welfare systems worldwide. This trend underscores the urgent need for countries to address MSDs as pressing public health and economic concerns.

Menopause is a defining characteristic of older women, marking the end of the reproductive years and accompanied by a significant decline in estrogen levels. Estrogen plays a crucial role in regulating various MSDs, including gout, OA, RA, and LBP [7]. The lack of estrogen exacerbates the risk of these conditions in PMW by contributing to decreased bone density, joint cartilage damage, and enhanced inflammatory responses. Specifically, estrogen deficiency has been linked to an increased frequency and severity of gout attacks, heightened activity in RA, and accelerated progression of OA and intervertebral disc degeneration [8, 9]. These changes render the musculoskeletal system of older women more vulnerable, leading to higher rates of joint pain, functional impairment, and reduced mobility [10, 11]. Despite the growing health concerns within this population, epidemiological research focusing on PMW remains sparse. Existing studies primarily concentrate on younger or reproductive-aged women or are limited to small-scale, localized cohorts [12, 13, 14]. There is a critical need for comprehensive, global epidemiological studies that address MSDs in PMW. Such research would be invaluable in understanding the full scope of these health risks and in developing targeted preventive and therapeutic strategies.

Figure 1 provides a visual summary of the study’s approach, illustrating the integration of global data on the prevalence and DALYs for key MSDs in PMW. The findings offer crucial insights into the increasing burden of these conditions, highlighting regional disparities and offering valuable epidemiological information for healthcare policies. These results can guide clinicians, epidemiologists, and policymakers in optimizing healthcare resource allocation to better address the MSDs burden in PMW.

Fig. 1.

Fig. 1

Schematic diagram of the analysis process

Materials and methods

Study population and data collection

This analysis focuses on a secondary analysis of the GBD. This analysis presents a secondary examination of the GBD database, with a particular focus on the epidemiology of MSDs. GBD 2021 employs a comprehensive data processing workflow designed to ensure the accuracy and consistency of estimates concerning the global burden of diseases.

In GBD 2021, the estimation process utilizes data from a total of 100,983 sources, including 19,189 that were newly incorporated in 2021. This extensive collection consists of systematic reviews of 369 diseases and 87 risk factors, alongside essential data gathered from surveys, disease registries, case reports, and hospitalization records. Noteworthy datasets from the Global Health Data Exchange (GHDx), such as the Demographic and Health Surveys (DHS), play a vital role in capturing a diverse range of health outcomes across various regions and populations. Among these sources, 75,459 specifically address nonfatal conditions, encompassing key epidemiological indicators such as incidence and prevalence [15].

To enhance the credibility of estimates related to years lived with disability (YLDs), years of life lost (YLLs), and DALYs, GBD 2021 utilizes sophisticated statistical models, including MR-BRT (Meta-regression-Bayesian, regularized, trimmed) and DisMod-MR 2.1. These models systematically adjust for biases that may arise from variations in data sources, definitions, and measurement techniques. MR-BRT is particularly effective in controlling for heterogeneity through network meta-regression, as well as performing sex-splitting for datasets that lack gender-specific reporting, and age-sex splitting for data not categorized by either dimension [16]. This methodology ensures internal consistency in estimates across different demographics, geographic areas, and time frames, thus addressing issues of heterogeneity in the results.

SDI

The SDI, developed by the Institute for Health Metrics and Evaluation (IHME) in 2015, evaluates the development levels of countries and regions, highlighting the link between social development and health outcomes. It is calculated as the geometric mean of three components: the total fertility rate for women under 25, the average educational attainment for those aged 15 and older, and lag-distributed income per capita. In the GBD 2021 analysis, SDI values range from 0 to 100, where 0 represents the lowest socioeconomic status (high fertility, low education, and low income) and 100 signifies the highest (low fertility, high education, and high income). The 204 countries and territories were classified into five SDI categories based on specific thresholds: low-SDI [0-0.4658), low-middle-SDI [0.4658–0.6188), middle-SDI [0.6188–0.7120), high-middle-SDI [0.7120–0.8103), and high-SDI [0.8103-1.0000]. This classification facilitates the analysis of how socioeconomic conditions affect health outcomes and further groups countries into 21 geographical regions, such as East Asia, reflecting regional disparities in development.

Estimated annual percentage change (EAPC)

This study analyzes the temporal trends in age-standardized rates (ASR) of prevalence and DALYs for MSDs from 1990 to 2021 by employing the EAPC as a key metric. The EAPC is calculated using a regression model that fits the natural logarithm of ASR against the calendar year, expressed by the equation y = α + βx + ε, where y represents the natural logarithm of the rates, x indicates the calendar year, α is the intercept, β is the slope, and ε denotes the error term. The EAPC itself is determined through the formula EAPC = 100 × (exp(β)-1). Trend interpretation relies on the 95% confidence intervals (CI) for the EAPC, with an increasing trend identified when both the EAPC and the lower CI limit are positive, while a decreasing trend is indicated if both are negative [17]. If the CIs encompass zero, it suggests no significant trend change. Data processing, analysis, and visualization were conducted using R software (version 4.3.1), employing the ggplot2 package for graphical representation and final adjustments made in Adobe Illustrator (version CS5), ensuring a comprehensive evaluation of MSDs trends over the specified period.

Decomposition analysis

We applied the Das Gupta decomposition method to analyze changes in MSDs burden from 1990 to 2021, attributing them to aging, population growth, and epidemiological shifts. This approach isolates each factor’s contribution, providing clearer insights into the drivers behind global and regional MSDs trends.

Cross-country health inequality analysis

This study utilized the SII and the concentration index to assess health disparities in disease burden across countries [18]. The SII quantifies absolute inequality by regressing DALYs against a relative position scale based on the SDI, defined by the midpoint of the cumulative population distribution. To address heteroskedasticity, we applied robust linear regression models, which reduce the influence of outliers. The concentration index measures relative inequality by fitting the cumulative health burden to the Lorenz curve, illustrating the distribution of health outcomes across populations ranked by SDI. Negative SII and concentration index values indicate that higher SDI corresponds to lower disease burden, with larger absolute values reflecting greater inequality [19, 20].

Projection analysis

We used the BAPC model to forecast the future burden of MSDs in PMW. The model, implemented via the BAPC R package, incorporates age, period, and cohort effects within a Bayesian framework. Bayesian inference was performed using the Integrated Nested Laplace Approximation (INLA) method, which efficiently approximates the marginal posterior distributions of model parameters, offering a computationally efficient alternative to Markov Chain Monte Carlo methods. For age, data were grouped into 5-year intervals (e.g., 55–59, 60–64, 65–69 years), reflecting the age-related risk of MSDs. The period variable was categorized by year to capture temporal trends, while the cohort effect was defined by year of birth to account for generational differences in disease patterns. Age and cohort effects were modeled with a second-order random walk prior, which smooths the data over time, while the period effect was treated as continuous to capture finer temporal variations. This methodology ensures robust, dynamic predictions of disease burden, providing insights into the future impact of musculoskeletal conditions in PMW [21].

Data analysis

To control the influence of different age structures on indicator comparisons, we calculated the ASR of major health burden indicators (prevalence, DALYs) per 100,000 PMW aged 55 to 95 using the following formula:

graphic file with name d33e417.gif

in the equation, r𝑖​ represents the rate for the 𝑖-th age group, w𝑖 denotes the standard population weight for the 𝑖-th age group, and N is the total number of age groups. The 95% CI were determined using the " ageadjust.direct " function in the “epitools” package of R software. We considered p < 0.05 to indicate statistical significance. All statistical analyses and graphical representations were performed using R software (version 4.3.1).

Result

Global, regional, and National burden of overall MSDs

According to United Nations statistics, the proportion of PMW in the total female population was 20% in 2021, compared to 13.75% in 1990 [22]. In both 2021 and 1990, the burden of MSDs among PMW was proportionally higher than the share of PMW in the total female population. RA, OA, and gout all exceeded 50%, demonstrating a clear postmenopausal predisposition. Specifically, in terms of prevalence, PMW with RA, OA, and gout were 1.5 times, 1.1 times, and 2.6 times higher, respectively, compared to premenopausal women. In terms of DALYs, PMW with RA, OA, and gout were 1.2 times, 3.1 times, and 2.9 times higher, respectively, compared to premenopausal women (Fig. 2A-D).

Fig. 2.

Fig. 2

Comparison of MSDs between premenopausal women and PWM across global regions in 1990 and 2021. A-D: The prevalence and DALYs of PMW as a percentage of the all-age females in 1990 and 2021. Panels (A) and (B) represent the prevalence and DALY percentage of PMW among all-age females in 2021, respectively. Panels (C) and (D) represent the prevalence and DALY percentage of PMW among all-age females in 1990, respectively. E-H: The global age-standardized prevalence and DALYs rates for MSDs in PMW across 204 countries in 2021, along with the EAPC from 1990 to 2021. Panels (E) and (F) represent the age-standardized prevalence and DALYs rates in 2021, respectively, while panels (G) and (H) depict the EAPC trends for age-standardized prevalence and DALYs rates from 1990 to 2021

In 2021, the global prevalence of MSDs in PMW was approximately 210,062,921 cases, with an age-standardized prevalence rate of 60,482 per 100,000 population, and DALYs amounted to approximately 45,039,175, with an age-standardized DALYs rate of 5,722 per 100,000 population. Among the 21 GBD geographical regions, the highest age-standardized prevalence rates were found in High-income Asia Pacific (70,215), Southern Latin America (69,098), and High-income North America (68,747), while the highest age-standardized DALYs rates were observed in Southern Latin America (7,244), High-income Asia Pacific (7,012), and Australasia (6,990). At the country or regional level, the highest age-standardized prevalence rates were found in Japan (70,617), the United States of America (69,639), and Chile, while the highest age-standardized DALYs rates were in Chile (7,283), Argentina (7,229), and Japan (7,224) (Fig. 2E-F; Table 1, Table S1).

Table 1.

Cases and age-standardized rates of prevalence and dalys in 1990 and 2021, and their estimated annual percentage changes from 1990 to 2021 for MSDs in PMW, globally and by 21 GBD regions

Characteristics 1990 2021 1990–2021 1990 2021 1990–2021
prevalent cases No. (95% CI) ASR per 100,000 No. (95% CI) prevalent cases No. (95% CI) ASR per 100,000 No. (95% CI) EAPC No. (95% CI) DALYs cases No. (95% CI) ASR per 100,000 No. (95% CI) DALYs cases No. (95% CI) ASR per 100,000 No. (95% CI) EAPC No. (95% CI)
Global 210062921.6 58444.23082 476105959.2 60482.06601 0.15 (0.13 to 0.17) 20263902.24 5620.667808 45039175.95 5722.737072 0.11 (0.09 to 0.13)
High SDI 66856844.71 62499.16653 122,694,853 65506.71071 0.17 (0.15 to 0.19) 6541002.954 6146.167211 11894693.82 6404.965213 0.15 (0.13 to 0.17)
High-income Asia Pacific 13261022.67 67588.21613 27578343.29 70214.88403 0.24 (0.15 to 0.33) 1343663.411 6835.029276 2718904.44 7011.585153 0.18 (0.1 to 0.26)
High-income North America 21655423.55 65141.16649 41776235.48 68746.86351 0.11 (0.08 to 0.15) 2121956.437 6452.504427 4108469.756 6795.935379 0.11 (0.09 to 0.13)
High-middle SDI 56956980.75 58549.17252 112592121.8 59667.93684 0.13 (0.1 to 0.15) 5474378.149 5613.718696 10470154.16 5554.251986 0.04 (0.01 to 0.07)
Middle SDI 49192403.39 55836.0228 143663645.5 58690.70752 0.24 (0.21 to 0.27) 4633774.787 5223.426218 13206652.08 5374.504913 0.19 (0.16 to 0.22)
Low-middle SDI 27350841.71 56030.06333 74042576.62 59339.71598 0.19 (0.16 to 0.21) 2681422.421 5455.96738 7259958.547 5793.181116 0.2 (0.16 to 0.24)
Low SDI 9465890.576 53103.714 22700302.47 54980.28753 0.11 (0.1 to 0.13) 910278.8867 5057.443008 2169136.695 5212.940868 0.11 (0.08 to 0.14)
Andean Latin America 950021.5347 55689.26223 3052576.106 59168.69471 0.21 (0.2 to 0.22) 83431.93994 4884.839979 270786.2825 5247.730341 0.26 (0.24 to 0.27)
Australasia 1412517.524 65273.01504 3176912.598 67870.57407 0.13 (0.11 to 0.14) 146046.3525 6747.874297 325650.2747 6989.628438 0.1 (0.06 to 0.13)
Caribbean 1157830.234 51965.27076 2684122.776 54703.81893 0.18 (0.18 to 0.19) 99772.98023 4478.164372 229615.9718 4684.390431 0.17 (0.16 to 0.18)
Central Asia 2707060.537 57176.91473 4925990.621 61525.93082 0.26 (0.23 to 0.28) 249296.7947 5259.802508 448740.7891 5607.051405 0.24 (0.22 to 0.27)
Central Europe 8958077.493 59459.49706 13157706.16 61791.17522 0.14 (0.13 to 0.14) 890934.5714 5901.7195 1283686.729 6074.372329 0.11 (0.1 to 0.12)
Central Latin America 4089015.081 58564.6436 14283807.65 62049.82341 0.19 (0.19 to 0.2) 398485.9359 5686.539467 1388488.345 6024.521697 0.2 (0.18 to 0.22)
Central Sub-Saharan Africa 1021266.633 52469.38288 2537892.37 53191.68456 0.02 (0 to 0.04) 94453.39338 4777.136081 232983.5918 4829.31627 0.02 (0.01 to 0.04)
East Asia 41479230.37 55194.52527 115016526.5 56962.62142 0.27 (0.21 to 0.33) 3866152.88 5103.331785 10168227.84 5020.837056 0.15 (0.09 to 0.22)
Eastern Europe 19892576.01 62601.04187 24846319.16 64283.86156 0.15 (0.13 to 0.17) 1952801.716 6130.700149 2451298.795 6347.356538 0.19 (0.15 to 0.22)
Eastern Sub-Saharan Africa 3053509.322 51696.20279 7403949.386 53436.34428 0.11 (0.1 to 0.12) 286674.4027 4805.750902 683098.9597 4893.237692 0.08 (0.07 to 0.09)
North Africa and Middle East 7357990.186 53975.49157 21782740.48 58565.91798 0.27 (0.26 to 0.28) 712850.9442 5190.612208 2099723.965 5608.258934 0.27 (0.26 to 0.28)
Oceania 115686.4732 51258.89597 306613.0182 53491.74151 0.14 (0.14 to 0.15) 10465.81351 4570.376635 27095.13476 4666.889541 0.09 (0.08 to 0.1)
South Asia 25957823.44 58475.30086 78486133.62 62162.18233 0.2 (0.16 to 0.24) 2575568.233 5765.636962 7757918.481 6114.417875 0.19 (0.11 to 0.26)
Southeast Asia 10884345.59 49132.24777 32052063.59 52929.38633 0.24 (0.24 to 0.25) 1013933.761 4541.328549 2953769.9 4848.948654 0.22 (0.22 to 0.23)
Southern Latin America 2917121.253 66284.09248 5662834.982 69098.29438 0.1 (0.07 to 0.13) 302349.3885 6860.772193 591576.5166 7243.76751 0.13 (0.07 to 0.19)
Southern Sub-Saharan Africa 1375863.434 55040.16706 3193182.067 56733.61149 0.13 (0.12 to 0.14) 129132.6985 5146.363039 291799.3653 5162.526686 0.06 (0.04 to 0.08)
Tropical Latin America 4872936.056 60752.82075 15418152.88 63462.07157 0.11 (0.09 to 0.13) 473236.9156 5855.481347 1492321.023 6142.054363 0.1 (0.06 to 0.14)
Western Europe 33352864.04 58845.51889 49751158.94 60849.38661 0.1 (0.1 to 0.11) 3182621.385 5650.863449 4690139.384 5812.287158 0.09 (0.08 to 0.1)
Western Sub-Saharan Africa 3590740.155 51899.67885 9012697.536 53848.16329 0.13 (0.12 to 0.13) 330072.2859 4734.152066 824880.4055 4875.5307 0.11 (0.1 to 0.12)

Abbreviations: ASR, age-standardised rate, DALY = disability-adjusted life-years. EAPC = estimated annual percentage change

From 1990 to 2021, the global age-standardized prevalence and DALYs rates for MSDs in PMW both increased, with an EAPC of 0.15 and 0.11, respectively. Among all geographical regions, High-income Asia Pacific (EAPC = 0.32), East Asia (EAPC = 0.28), and North Africa and the Middle East (EAPC = 0.27) experienced the fastest growth in age-standardized prevalence rates, while North Africa and the Middle East (EAPC = 0.27), Andean Latin America (EAPC = 0.27), and North Africa and the Middle East (EAPC = 0.27) showed the fastest increases in age-standardized DALYs rates. At the country or regional level, Equatorial Guinea (EAPC = 0.48), Armenia (EAPC = 0.41), and Lebanon (EAPC = 0.39) experienced the fastest growth in age-standardized prevalence rates, while Taiwan (Province of China) (EAPC = 0.64), United Arab Emirates (EAPC = 0.53), and Eritrea (EAPC = 0.49) had the fastest increases in age-standardized DALYs rates (Fig. 2G-H; Table 1, Table S1).

Regional differences in the burden of six MSDs in PMW

In 2021, the global numbers of prevalence for RA, OA, LBP, NP, gout, and OMSKDs MSDs in PMW was 7,137,825 cases, 278,568,950 cases, 176,831,236 cases, 44,474,377 cases, 10,637,684 cases, and 116,360,357 cases, respectively. The corresponding age-standardized prevalence rates per 100,000 population were 906, 35,345, 22,461, 5,660, 1,347, and 14,804. The global DALYs for these six diseases and their age-standardized DALYs rates per 100,000 population were 1,313,807 (167), 9,944,716 (1,262), 19,078,108 (2,424), 4,217,620 (537), 314,593 (40), and 10,170,331 (1,294), respectively (Fig. 3A-B).

Fig. 3.

Fig. 3

The age-standardized prevalence rates and DALYs rates of MSDs among PMW in 2021 globally and across 21 GBD regions, along with the EAPC from 1990 to 2021. A-B: Trends in age-standardized prevalence rates (A) and DALYs rates (B) of MSDs among PMW in 2021, globally and across 21 GBD regions. C-D: The EAPC of age-standardized prevalence rates (C) and DALYs rates (D) of MSDs among PMW from 1990 to 2021, globally and across 21 GBD regions. Bars reflect the magnitude and direction of change, with positive values indicating an increase and negative values indicating a decrease

At the national level,, the highest age-standardized prevalence rates for RA, OA, LBP, NP, gout, and OMSKDs were found in Ireland (2,979), Republic of Korea (48,280), Ukraine (36,485), Iran (Islamic Republic of) (11,455), United States of America (3,004), and Bangladesh (30,535), while the highest age-standardized DALYs rates were in Ireland (460), Republic of Korea (1,817), Ukraine (3,936), Iran (Islamic Republic of) (1,078), United States of America (87), and Bangladesh (2,593) (Figure S1-2, Table S1-7).

From 1990 to 2021, except for LBP (EAPC = -0.28), which showed a significant decline in age-standardized prevalence rate, RA (EAPC = 0.54), OA (EAPC = 0.34), gout (EAPC = 0.93), and OMSKDs (EAPC = 0.75) showed significant increases. NP (EAPC = 0.04) showed little change. The global trends in age-standardized DALYs rate were similar to those in prevalence rates, with significant declines in LBP (EAPC = -0.29) and RA (EAPC = -0.08), and significant increases in OA (EAPC = 0.38), gout (EAPC = 0.91), and OMSKDs (EAPC = 0.72) (Figure S3-4, Table S1-7).

The age-standardized of six MSDs rate in PMW shows significant disease patterns and regional differences. LBP and OA are the leading contributors to the disease burden, both in prevalence and DALYs. The data indicates that LBP contributes the most to the age-standardized DALYs rate globally, particularly in East Asia, South Asia, and Sub-Saharan Africa, where its burden is significantly higher than that of other MSDs. Meanwhile, the prevalence of OA has shown a consistent increase across all regions, especially in South Asia, indicating the widespread nature and severity of the disease. NP and RA have a notably higher impact in high-income regions, such as North America, Western Europe, and High-income Asia Pacific. In particular, NP ranks highly in terms of both prevalence and DALYs in these regions, and the EAPC in DALYs for RA has shown a marked increase in some areas like North America and Western Europe, indicating that the disease burden in these high-income regions is increasing. Gout, although contributing less to the overall global disease burden, shows significant annual change rates in regions like High-income North America and East Asia. Additionally, the prevalence and DALYs of OMSKDs have remained relatively stable globally, with some regions, such as Sub-Saharan Africa, facing a higher burden, but the overall contribution to the global disease burden remains limited (Fig. 3C-D, Table S8-13).

The analysis of prevalence and DALYs numbers for the six MSDs shows that East Asia, South Asia, and Western Europe bear the heaviest burden of MSDs, with East Asia being particularly prominent (Fig. 4A-B). Due to its large population, East Asia recorded the highest global prevalence and DALYs for all types of MSDs. Specifically, LBP, OA, and NP were the most significant contributors to the disease burden in these regions. Based on the number of prevalence and DALYs cases, we further calculated the proportion of each disease in the total MSDs burden across regions. In the analysis of prevalence proportions (Fig. 4C), OA accounted for the highest proportion in many regions, particularly in the Caribbean, where its prevalence proportion reached 51.29%. Gout had the highest prevalence proportion in High-income North America, while NP and RA showed the highest prevalence proportions in North Africa and the Middle East. Central Europe had the highest proportion of LBP prevalence, whereas OMSKDs had the highest prevalence proportion in Southern Latin America. In the analysis of DALYs proportions for MSDs across regions, LBP accounted for the highest proportion of the MSDs burden. Central and Eastern Europe, sub-Saharan Africa, and Central Asia bear the highest proportion of DALYs caused by LBP, accounting for over 50% of DALYs attributed to the six MSDs. OA had the highest proportion in the Caribbean, gout in High-income North America, NP in North Africa and the Middle East, RA in Central Latin America, and OMSKDs in South Asia (Fig. 4D).

Fig. 4.

Fig. 4

Prevalence and DALYs of MSDs among PMW across 21 GBD Regions in 2021. A: The total number of prevalence cases of MSDs among PMW across 21 GBD regions in 2021. B: The total number of DALYs cases of MSDs among PMW in the 21 GBD regions in 2021. C: The proportional distribution of prevalence cases among MSDs across the 21 GBD regions in 2021. D: The proportional distribution of DALYs among MSDs across the 21 GBD regions in 2021. Each bar represents different types of MSDs, including RA, OA, LBP, NP, gout, and OMSKDs. The colors in the bars correspond to different MSD types, as indicated in the legend

Age-group disparities in the burden of six MSDs

In 2021, significant differences were observed in the age distribution of prevalence, and DALYs rates for six MSDs. Firstly, the age group of 55–74 years bore the highest global burden of MSDs. Secondly, LBP and OA were identified as the two most impactful conditions on health, particularly in the 55–79 age group, where they accounted for a substantial proportion of the burden. The prevalence and DALYs for gout, NP and RA were relatively low across all age groups, indicating that their overall health burden was comparatively minor. OMSKDs had a higher prevalence in middle-aged and early elderly women (55 to 74 years), but their proportion gradually decreased with increasing age (Fig. 5A-B).

Fig. 5.

Fig. 5

Prevalence and DALYs of MSDs among PMW across different age groups. A: The number of prevalence cases of MSDs in PMW across different age groups. Each bar represents the distribution of six types of MSDs: RA, OA, LBP, NP, gout, and OMSKDs. B: The number of DALYs associated with MSDs in PMW across different age groups. Similar to panel A, the distribution is shown for six types of MSDs, illustrating the relative burden of each disorder. C: The rate of prevalence of MSDs among PMW across different age groups. This line graph shows the prevalence rate trends for each MSD type, highlighting the age-related changes in burden. D: The rate of DALYs due to MSDs among PMW across different age groups. This graph shows how the DALY rates for each MSD type vary across the lifespan, highlighting which disorders contribute most significantly to the disability burden at different ages

On the other hand, the prevalence and DALYs rates for these diseases in PMW differed. OA showed the most significant increase among all diseases, particularly in those over 75, where it reached higher levels. RA remained relatively low across all age groups, with a relatively flat trend showing no significant increase or decrease. LBP peaked in the 75–84 age group and then gradually declined. OMSKDs peaked in the 70–74 age group and also gradually decreased thereafter. The turning point for the increase in NP occurs at age 65, with a rising trend observed before this age. After 65, a decline begins, becoming more pronounced by age 75. Gout showed a mild upward trend across all age groups (Fig. 5C-D).

SDI correlation

Between 1990 and 2021, across the 21 GBD regions, the overall age-standardized DALYs rates for MSDs exhibited a complex pattern of correlation with the SDI. As SDI increased, the overall age-standardized DALYs rates tended to rise, particularly for MSDs (ρ = 0.42, P < 0.001), OA (ρ = 0.76, P < 0.001), RA (ρ = 0.31, P < 0.001) and gout (ρ = 0.47, P < 0.001), which showed significant increases in age-standardized DALYs rates in high SDI regions, reflecting their strong dependence on socioeconomic development levels. In contrast, the correlation between SDI and LBP (ρ = 0.20, P < 0.001) and NP (ρ = 0.06, P < 0.001) was lower, with age-standardized DALYs rates more evenly distributed across regions. The age-standardized DALYs rate for OMSKDs displayed a “bimodal” pattern with SDI, showing an increasing trend in both low and high SDI regions, while it remained relatively stable in medium SDI regions. These results highlight the diverse relationship between different types of MSDs and SDI globally, underscoring the significant differences in disease burden between high-income and low-income regions (Figure S5).

Building on the findings above, we further explored the relationship between MSDs in PMW and the SDI. The study revealed that while RA showed a declining trend in high-SDI regions, it exhibited an annual increase in low- and middle-SDI regions. OA, gout, and OMSKDs demonstrated a consistent annual rise across all SDI levels. In contrast, LBP showed a steady decline across all SDI categories. The results for NP were particularly intriguing, with a decline observed since 1995, followed by a significant increase in 2005. Another notable finding was that the disease burden in high- and low-SDI regions decreased more significantly compared to middle-SDI regions. Among MSDs, gout stood out as the only condition with a progressive increase in burden as SDI rose, highlighting its importance for further attention (Fig. 6).

Fig. 6.

Fig. 6

The association between the DALY rates of MSDs in PMW from 1990 to 2021 and the SDI. A-F: Trends in age-standardized DALYs rates for MSDs among PMW from 1990 to 2021 across different SDI levels. The figures represent: A: RA. B: OA. C: LBP. D: NP. E: Gout. F: OMSKDs. G: The EAPC of age-standardized DALYs rates for MSDs among PMW from 1990 to 2021 across different SDI levels. Bars reflect the magnitude and direction of change, with positive values indicating an increase and negative values indicating a decrease

Cross-country inequalities of MSDs in PMW, 1990–2021

First, from the perspective of the inequality slope index, there were significant differences in the correlation between the age-standardized DALYs rates of different types of MSDs and the SDI between 1990 and 2021. Over the past three decades, the burden of RA, OA, LBP, gout, and OMSKDs has been significantly heavier in high SDI regions, reflecting the concentration of these diseases in high SDI areas. Notably, OA (Figure S6A-C) exhibited the largest increase in disease burden among all MSDs in high SDI regions between 1990 and 2021. Additionally, NP (Figure S6D), which was primarily concentrated in low SDI regions in 1990, reversed this trend by 2021, with the burden shifting more towards high SDI regions.

From the perspective of the relative concentration index, significant differences and trend changes in the distribution of disease burden were observed for different MSDs between 1990 and 2021. The concentration indices for RA (Figure S6G) and OA (Figure S6H) decreased from 0.13 to 0.09 in 1990 to 0.07 in 2021, indicating a reduction in the concentration of these diseases in high SDI regions. However, the relative concentration index for gout (Figure S6K) increased from 0.07 in 1990 to 0.13 in 2021, suggesting that the burden of gout has become more concentrated in high SDI regions. The concentration index for LBP (Figure S6I) remained unchanged at 0.04 in both 1990 and 2021, indicating a consistent distribution of its burden between high SDI and low SDI regions. The concentration indices for NP (Figure S6J) and OMSKDs (Figure S6L) also showed notable trends. For NP, the concentration index was close to 0 in 1990 (-0.01) and slightly turned positive by 2021 (0.01). Similarly, the concentration index for OMSKDs decreased slightly from 0.01 in 1990 to -0.03 in 2021.

Decomposition analysis

From 1990 to 2021, with the exception of LBP, which showed a significant epidemiological decline globally and in High SDI, High-middle SDI, Middle SDI, East Asia, and South Asia, factors such as aging, population size, and epidemiological changes contributed to the continuous increase in the disease burden of MSDs, OA, NP, RA, gout, and OMSKDs. Among these factors, population size was the primary driver of the increased disease burden in all regions associated with MSDs, accounting for over 70% of the burden (Figure S7).

Future forecasts of global burden of MSDs in PMW

Globally, the burden of MSDs in PMW is projected to rise significantly between 2021 and 2045. Based on predictions from the BAPC model, by 2045, the prevalence number of RA cases will increase from 7,137,791.30 in 2021 to 13,948,183.52, OA will rise from 278,568,904.05 to 553,315,714.03, LBP will increase from 176,831,144.16 to 278,515,476.09, NP from 43,205,034.77 to 83,305,705.32, gout from 10,637,831.52 to 21,214,559.64, and OMSKDs from 116,360,264.30 to 313,452,229.62. In terms of age-standardised prevalence rate, gout will slightly decrease from 1,346.73 in 2021 to 1,344.96 in 2045, while LBP will drop from 22,460.85 to 19,544.66, and RA will increase from 906.05 to 989.13. The prevalence of other diseases will continue to rise, including NP from 5,660.00 to 6,076.37, OA from 35,344.63 to 38,584.74 (95% CI: 20,224.10–56,945.38), and OMSKDs from 14,804.06 to 19,292.66. The forecasted prevalence of OA suggests that by 2045, approximately 50% of PMW will suffer from this disease (Fig. 7A).

Fig. 7.

Fig. 7

The time trends of prevalence and DALYs, as well as their ASR for MSDs in PMW from 1990 to 2045. A: The prevalence for MSDs in PMW from 1990 to 2045, with the dashed vertical line separating historical data (1990–2021) and projected data (2021–2045). The bars represent the number of cases, and the lines show the rate of prevalence per 100,000 populations. B: The DALYs for MSDs in PMW, following the same format as Panel A, showing historical DALYs (1990–2021) and projected DALYs (2021–2040). The bars represent the number of DALYs, and the lines show the rate of DALYs per 100,000 populations

Although the age-standardised DALYs rate for some diseases is expected to decrease, such as gout, which will drop from 39.86 in 2021 to 39.63 in 2045, LBP from 2,424.07 to 2,052.33, and RA from 166.59 to 159.82, the DALYs burden for other diseases will rise. Specifically, NP will increase from 536.91 to 565.93, OA from 1,261.67 to 1,357.89, and OMSKDs from 1,293.63 to 1,316.55 per 100,000 population. These results indicate that the global burden of MSDs in PMW will significantly increase from 2021 to 2045, especially for OA and LBP, highlighting the need for more targeted public health interventions and resource allocation strategies (Fig. 7B).

Discussion

This study represents the first systematic assessment of the prevalence and DALYs of This study represents the first systematic assessment of the prevalence and DALYs of MSDs in PMW, and offers a comprehensive exploration of the global burden of these diseases. Our main findings are as follows: (1) The burden of MSDs among PMW is significantly higher than that among the general population, particularly for RA, OA, and gout. PMW account for more than 50% of all female-related cases, highlighting the high prevalence of these conditions in this specific demographic. (2) From 1990 to 2021, the global age-standardized prevalence and DALYs rates for MSDs in PMW have increased. LBP is the leading MSDs burden, whereas OA is the most prevalent disease. (3) OA, as the leading MSDs in PMW, continues to rise with age, and it is regarded as an inevitable “nightmare” for every PMW. By 2045, OA may affect 50% of the PMW. (4) Gout progresses slowly, but the significant growth trend in high-SDI regions, particularly in the United States, warrants serious attention.

According to research findings, data from the United Nations Department of Economic and Social Affairs reveals that the global population of PMW increased from 360 million in 1990 to 790 million in 2019, reflecting a 117% growth. The proportion of PMW among females of all age groups rose from 13.7% in 1990 to 20% in 2019. By 2021, MSDs were significantly more prevalent among PMW compared to the general female population, far exceeding the 20% proportion. Conditions such as RA, OA, and gout affected over 50% of PMW, particularly OA and gout. While previous studies have explored the relationships between menopause and conditions like RA, OA, LBP, NP, gout, and OMSKDs, there remains a considerable lack of research on the epidemiological characteristics of this specific demographic [23, 24, 25, 26, 27, 28].

Among MSDs in PMW, LBP and OA stand out as the most significant threats, collectively accounting for over 70% of cases. The global prevalence of LBP has shown a declining trend, largely due to the spread of health education, advancements in pain management techniques, and improvements in medical interventions, which have significantly reduced the risk of chronic LBP [29, 30, 31]. On the other hand, OA has worsened due to aging populations, rising obesity rates, and declining estrogen levels after menopause, all contributing to joint degeneration [32, 33, 34]. Moreover, improved diagnostic techniques have led to a significant increase in the reporting of early-stage OA cases, further highlighting its disease burden. Notably, the incidence of RA has declined in regions with a high SDI, such as high-income Asia Pacific, Australia, Central Europe, and Western Europe, likely due to improvements in disease management. However, in other regions, its prevalence and DALYs continues to rise. Furthermore, gout, NP, and OMSKDs mostly show upward trends, with declines observed only in a few areas.

From the perspective of global disease burden, the highest numbers of MSDs cases among PMW are concentrated in East Asia, South Asia, and Western Europe. This phenomenon is influenced not only by the large populations in these regions but also by dietary, environmental, and lifestyle factors that significantly impact musculoskeletal health. For example, in East Asia (e.g., Japan, China, and South Korea), insufficient calcium intake and low dairy consumption contribute to high rates of osteoporosis [35]. In South Asia (e.g., India), widespread vitamin D deficiency, driven by traditional clothing limiting sun exposure and diets lacking vitamin D-rich foods, is a major concern [36]. Conversely, in Western Europe, although dietary calcium intake is relatively high, advanced aging and increased life expectancy have led to a sustained rise in MSDs cases. Additionally, improved access to medical resources, higher diagnostic accuracy, and enhanced public health awareness in these regions have further driven up reported cases.

Our findings indicate that MSDs among PMW exhibit significant age dependence and dynamic changes in epidemiology. As age increases, the prevalence and DALYs of OA and gout rise sharply, primarily due to the complex biological mechanisms of aging, including degenerative changes in joints, metabolic disorders, and inflammation and cartilage degradation triggered by estrogen deficiency [37]. Furthermore, the high prevalence of comorbidities such as obesity, hypertension, and diabete exacerbates the progression of OA and gout [38, 39]. These conditions not only have a high disabling potential but also place a significant strain on healthcare resources and impose a substantial economic burden on patients. In contrast, the DALYs of LBP peaks between the ages of 75 and 84, followed by a gradual decline. This pattern may be driven by multiple factors, including reduced physical activity in older adults, which lessens mechanical strain, diminished pain perception due to neural degeneration, and the cumulative effects of long-term medical interventions (e.g., physical therapy or surgery) alleviating symptoms. Additionally, the “healthy survivor effect,” where healthier individuals comprise a greater proportion of older age groups, may also contribute [40]. Nevertheless, LBP continues to significantly affect the quality of life and functional status of elderly women, especially in its early stages.

In 2021, the burden of MSDs among PMW displayed complex trends across varying SDI levels. While the EAPC for RA, NP, and LBP decreased, the overall disease burden remained substantial. Conversely, the burden of gout increased significantly, with notable growth in EAPC, even in high-SDI regions. The declining burden of RA, NP, and LBP in high-SDI regions can be attributed to improved medical resources, the widespread adoption of early screening, and heightened health awareness. For instance, the decrease in RA in high-income regions may be linked to the widespread use of biologics (e.g., anti-TNF drugs), which effectively reduce inflammation and disease activity [41]. In contrast, in middle- and low-income regions, limited access to medical resources and the prohibitive cost of biologic treatments hinder effective disease management, resulting in rising prevalence rates. High-SDI regions’ focus on quality of life and long-term functional impairments has also exacerbated the rise in DALYs. By contrast, low-SDI regions face challenges such as underdiagnosis and resource scarcity, where delayed treatment often leads to severe late-stage disease. Particularly for gout, its burden and EAPC increase in high-SDI regions align with dietary habits (e.g., consumption of purine-rich red meat and seafood), a high prevalence of metabolic disorders, and sedentary lifestyles [42, 43]. The loss of estrogen’s protective effects in PMW further heightens the risk of gout caused by purine metabolism disorders. In addition, factors such as rising obesity rates and the prevalence of chronic diseases (e.g., diabetes and hypertension) in high-SDI countries like the United States have worsened this trend [44, 45]. Advanced monitoring and diagnostic technologies in these regions also enhance disease detection, partially explaining the EAPC growth with increasing SDI levels.

The high prevalence and complexity of MSDs in PMW necessitate comprehensive and precise management strategies. Interventions should prioritize early prevention by controlling body weight, optimizing metabolic functions, and supplementing estrogen to slow disease progression [46]. Multidisciplinary management should be integrated to develop personalized health plans that improve treatment outcomes. In high-SDI regions like Western Europe and Australia, efforts should focus on addressing the rising burden of metabolic diseases like gout by promoting dietary and lifestyle improvements, such as reducing purine-rich food intake and increasing physical activity. In low-SDI regions, the emphasis should be on health education and early disease screening to enhance diagnostic and treatment coverage. Public health policies must also account for age-related disease burden and SDI disparities. The decline in RA in high-income regions demonstrates the effectiveness of systematic management and early intervention, which should be widely adopted. The reduction in LBP burden further highlights the success of pain management strategies, which can be applied to OMSKDs. Additionally, exploring the potential of hormone replacement therapy (HRT) and examining the relationship between hormone decline and metabolic disorders could provide new insights [47, 48]. Evaluating the long-term impacts of dietary and lifestyle changes on disease burden will also be crucial. Ensuring equitable and accurate data monitoring will support tailored disease prevention strategies across diverse socioeconomic settings, ultimately helping to extend healthy lifespans and improve the quality of life for PMW.

This study has several limitations, as outlined below: 1. The data used in this study were derived from mathematical modeling rather than direct measurements, which may inevitably introduce discrepancies with real-world conditions.2. The GBD 2021 data still lacks reliable epidemiological data from low- and middle-income countries, which may lead to an underestimation of the true disease burden in these regions.3. OMSKDs include a wide range of heterogeneous diseases, resulting in varying epidemiology. Due to the limitations of the GBD database, we were unable to conduct separate statistical analysis for these disorders.

Conclusion

This study represents the first systematic assessment of the global burden of MSDs on PMW. Our findings reveal that the disease burden has been increasing from 1990 to 2021, and is expected to continue to increase in the future. High SDI regions face the greatest burden due to aging populations and lifestyle changes, whereas middle- and low-SDI regions encounter new challenges due to urbanization and changes in work patterns. These insights offer critical epidemiological data that can guide healthcare policies and optimize resource allocation, enabling more effective management and intervention strategies for MSDs across different regions. Addressing the health needs of older women should be a priority for future public health strategies, particularly in the context of aging societies. Strengthening the prevention, early detection, and management of MSDs will not only improve the quality of life for PMW but also alleviate the growing social and economic burden posed by these conditions.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1 (24.6MB, docx)

Acknowledgements

First and foremost, we extend our gratitude to the Institute for Health Metrics and Evaluation at the University of Washington, the GBD collaborators, and all the staff who provided the essential data for this study.

Abbreviations

GBD

Global Burden of Disease

PMW

Postmenopausal women

MSDs

Musculoskeletal disorders

RA

Rheumatoid arthritis

OA

Osteoarthritis

LBP

Low back pain

NP

Neck pain

OMSKDs

Other musculoskeletal conditions

DALYs

Disability-Adjusted Life Years

YLDs

Years lived with disability

YLLs

Years of life lost

ASR

Age-standardized rates

EAPC

Estimated annual percentage change

BAPC

Bayesian Age-Period-Cohort

SII

Slope Index of Inequality

GHDx

Global Health Data Exchange

DHS

Demographic and Health Surveys

MR-BRT

Meta-regression-Bayesian, regularized, trimmed

Author contributions

WH and YTL conceived and designed the study. JYT and JYL contributed to drafting the manuscript and collecting GBD data. JYT, ZLZ, and XKW conducted age standardization and decomposition analysis of the GBD data. JYT, BSY, SRL, MLS, CCD, YSS and YJL participated in discussions regarding the GBD data, as well as the verification and validation of the manuscript’s data. All authors have reviewed and approved the final version of the manuscript.

Funding

This research was supported by grants from the National Natural Science Foundation of China (U22A20284, 82460548), the Qian De Outstanding Young Talent Program of The First Affiliated Hospital of Chongqing Medical University (2025QDYQ-09), Chongqing Medical Youth Top-notch Talent Program (YXQN202490), the China Postdoctoral Science Foundation (2024M753873), Hong Kong Scholars Program (XJ2024017), and Natural Science Foundation of Chongqing, China (CSTB2024NSCQ-MSX1200).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jianye Tan, Zhenglin Zhu and Xingkuan Wang share first authorship.

Contributor Information

Junyi Liao, Email: liaojunyi@cqmu.edu.cn.

Yiting Lei, Email: leiyit614@163.com.

Wei Huang, Email: huangw511@163.com.

References

  • 1.Smolen JS. Combating the burden of musculoskeletal conditions. ANN RHEUM DIS. 2004;63(4):329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Briggs AM, Woolf AD, Dreinhöfer K, Homb N, Hoy DG, Kopansky-Giles D, Åkesson K, March L. Reducing the global burden of musculoskeletal conditions. B WORLD HEALTH ORGAN. 2018;96(5):366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Safiri S, Kolahi AA, Cross M, Hill C, Smith E, Carson Chahhoud K, Mansournia MA, Almasi Hashiani A, Ashrafi Asgarabad A, Kaufman J. Prevalence, deaths, and disability-adjusted life years due to musculoskeletal disorders for 195 countries and territories 1990–2017. ARTHRITIS RHEUMATOL. 2021;73(4):702–14. [DOI] [PubMed] [Google Scholar]
  • 4.Cieza A, Causey K, Kamenov K, Hanson SW, Chatterji S, Vos T. Global estimates of the need for rehabilitation based on the global burden of disease study 2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10267):2006–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lagace C, O Donnell S, McRae L, Badley E, MacKay C. Life with arthritis in Canada. A personal and public health challenge, 2010. URL: https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/cd-mc/arthritis-arthrite/lwaic-vaaac-10/pdf/arthritis-2010-eng.pdf. [PubMed]
  • 6.Murphy LB, Cisternas MG, Pasta DJ, Helmick CG, Yelin EH. Medical expenditures and earnings losses among US adults with arthritis in 2013. ARTHRIT CARE RES. 2018;70(6):869–76. [DOI] [PubMed] [Google Scholar]
  • 7.Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA, Bouillon R, Vanderschueren D, Manolagas SC. Estrogens and androgens in skeletal physiology and pathophysiology. PHYSIOL REV. 2017;97(1):135–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yang S, Zhang F, Ma J, Ding W. Intervertebral disc ageing and degeneration: the antiapoptotic effect of oestrogen. AGEING RES REV. 2020;57:100978. [DOI] [PubMed] [Google Scholar]
  • 9.Pang H, Chen S, Klyne DM, Harrich D, Ding W, Yang S, Han FY. Low back pain and osteoarthritis pain: a perspective of Estrogen. BONE RES. 2023;11(1):42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. ANN RHEUM DIS. 2010;69(7):1305–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Islander U, Jochems C, Lagerquist MK, Forsblad-d Elia H, Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. MOL CELL ENDOCRINOL. 2011;335(1):14–29. [DOI] [PubMed] [Google Scholar]
  • 12.Cao F, Li D, Wu G, He Y, Liu Y, Hou J, Ni Q, Tao L, Jiang Z, Pan H. Global, regional and National Temporal trends in prevalence for musculoskeletal disorders in women of childbearing age, 1990–2019: an age-period-cohort analysis based on the global burden of disease study 2019. ANN RHEUM DIS. 2024;83(1):121–32. [DOI] [PubMed] [Google Scholar]
  • 13.Guan S, Zheng J, Sam NB, Xu S, Shuai Z, Pan F. Global burden and risk factors of musculoskeletal disorders among adolescents and young adults in 204 countries and territories, 1990–2019. AUTOIMMUN REV. 2023;22(8):103361. [DOI] [PubMed] [Google Scholar]
  • 14.Weng Q, Chen Q, Jiang T, Zhang Y, Zhang W, Doherty M, Xie J, Liu K, Li J, Yang T. Global burden of early-onset osteoarthritis, 1990–2019: results from the global burden of disease study 2019. ANN RHEUM DIS. 2024;83(7):915–25. [DOI] [PubMed] [Google Scholar]
  • 15.Bai Z, Han J, An J, Wang H, Du X, Yang Z, Mo X. The global, regional, and national patterns of change in the burden of congenital birth defects, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2040. ECLINICALMEDICINE 2024, 77. [DOI] [PMC free article] [PubMed]
  • 16.Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, Abd ElHafeez S, Abdelmasseh M, Abd-Elsalam S, Abdollahi A. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2133–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hankey BF, Ries LA, Kosary CL, Feuer EJ, Merrill RM, Clegg LX, Edwards BK. Partitioning linear trends in age-adjusted rates. CANCER CAUSE CONTROL. 2000;11:31–5. [DOI] [PubMed] [Google Scholar]
  • 18.Cao F, He Y, Wang Y, Zha C, Lu J, Tao L, Jiang Z, Pan H. Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019. AUTOIMMUN REV. 2023;22(6):103326. [DOI] [PubMed] [Google Scholar]
  • 19.Jin Y, Guo C, Abbasian M, Abbasifard M, Abbott JH, Abdullahi A, Abedi A, Abidi H, Abolhassani H, Abu-Gharbieh E. Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050. MED-CAMBRIDGE 2024. [DOI] [PMC free article] [PubMed]
  • 20.Ordunez P, Martinez R, Soliz P, Giraldo G, Mujica OJ, Nordet P. Rheumatic heart disease burden, trends, and inequalities in the americas, 1990–2017: a population-based study. Lancet Global Health. 2019;7(10):e1388–97. [DOI] [PubMed] [Google Scholar]
  • 21.Knoll M, Furkel J, Debus J, Abdollahi A, Karch A, Stock C. An R package for an integrated evaluation of statistical approaches to cancer incidence projection. BMC MED RES METHODOL. 2020;20:1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.United N, Department OEAS, Population D. World population prospects 2024, online edition. [Online]: United Nations; 2024. [Google Scholar]
  • 23.Collaborators GG. Global, regional, and National burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2024;6(8):e507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Gill TK, Mittinty MM, March LM, Steinmetz JD, Culbreth GT, Cross M, Kopec JA, Woolf AD, Haile LM, Hagins H. Global, regional, and National burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2023;5(11):e670–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Steinmetz JD, Culbreth GT, Haile LM, Rafferty Q, Lo J, Fukutaki KG, Cruz JA, Smith AE, Vollset SE, Brooks PM. Global, regional, and National burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021. Lancet Rheumatol. 2023;5(9):e508–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ferreira ML, De Luca K, Haile LM, Steinmetz JD, Culbreth GT, Cross M, Kopec JA, Ferreira PH, Blyth FM, Buchbinder R. Global, regional, and National burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2023;5(6):e316–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wu A, Cross M, Elliott JM, Culbreth GT, Haile LM, Steinmetz JD, Hagins H, Kopec JA, Brooks PM, Woolf AD. Global, regional, and National burden of neck pain, 1990–2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2024;6(3):e142–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, Kopec JA, Brooks PM, Woolf AD, Ong KL. Global, regional, and National burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2023;5(10):e594–610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.O’Keeffe M, O’Sullivan P, Purtill H, Bargary N, O’Sullivan K. Cognitive functional therapy compared with a group-based exercise and education intervention for chronic low back pain: a multicentre randomised controlled trial (RCT). BRIT J SPORT MED. 2020;54(13):782–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Pocovi NC, Lin CC, French SD, Graham PL, van Dongen JM, Latimer J, Merom D, Tiedemann A, Maher CG, Clavisi O. Effectiveness and cost-effectiveness of an individualised, progressive walking and education intervention for the prevention of low back pain recurrence in Australia (WalkBack): a randomised controlled trial. Lancet 2024. [DOI] [PubMed]
  • 31.Wu Y, Hanson SW, Culbreth G, Purcell C, Brooks P, Kopec J, March L, Woolf AD, Pasovic M, Hamilton E. Assessing the impact of health-care access on the severity of low back pain by country: a case study within the GBD framework. Lancet Rheumatol. 2024;6(9):e598–606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tang X, Wang S, Zhan S, Niu J, Tao K, Zhang Y, Lin J. The prevalence of symptomatic knee osteoarthritis in china: results from the China health and retirement longitudinal study. ARTHRITIS RHEUMATOL. 2016;68(3):648–53. [DOI] [PubMed] [Google Scholar]
  • 33.Reyes C, Leyland KM, Peat G, Cooper C, Arden NK, Prieto Alhambra D. Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study. ARTHRITIS RHEUMATOL. 2016;68(8):1869–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Berenbaum F, Wallace IJ, Lieberman DE, Felson DT. Modern-day environmental factors in the pathogenesis of osteoarthritis. NAT REV RHEUMATOL. 2018;14(11):674–81. [DOI] [PubMed] [Google Scholar]
  • 35.Cheung EY, Tan KC, Cheung C, Kung AW. Osteoporosis in East asia: current issues in assessment and management. Osteoporos Sarcopenia. 2016;2(3):118–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Akhtar S. Vitamin D status in South Asian populations–risks and opportunities. CRIT REV FOOD SCI. 2016;56(11):1925–40. [DOI] [PubMed] [Google Scholar]
  • 37.Kell RT, Bell G, Quinney A. Musculoskeletal fitness, health outcomes and quality of life. SPORTS MED. 2001;31:863–73. [DOI] [PubMed] [Google Scholar]
  • 38.Eun Y, Kim I, Han K, Lee KN, Lee D, Shin DW, Kang S, Lee S, Cha H, Koh E. Association between female reproductive factors and gout: a nationwide population-based cohort study of 1 million postmenopausal women. ARTHRITIS RES THER. 2021;23(1):304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC MED. 2017;15:1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Murphy TE, Han L, Allore HG, Peduzzi PN, Gill TM, Lin H. Treatment of death in the analysis of longitudinal studies of gerontological outcomes. Journals Gerontol Ser A: Biomedical Sci Med Sci. 2011;66(1):109–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Hsieh P, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. ANN RHEUM DIS. 2020;79(6):771–7. [DOI] [PubMed] [Google Scholar]
  • 42.Choi HK. Diet, alcohol, and gout: how do we advise patients given recent developments? CURR RHEUMATOL REP. 2005;7(3):220–6. [DOI] [PubMed] [Google Scholar]
  • 43.Hak AE, Choi HK. Lifestyle and gout. CURR OPIN RHEUMATOL. 2008;20(2):179–86. [DOI] [PubMed] [Google Scholar]
  • 44.Rosa S, Martins D, Martins M, Guimarães B, Cabral L, Horta L. Body mass index and musculoskeletal pain: a cross-sectional study. CUREUS J MED Sci 2021, 13(2). [DOI] [PMC free article] [PubMed]
  • 45.Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, Redon J, Stack AG, Tsioufis KP. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. EUR J INTERN MED. 2020;80:1–11. [DOI] [PubMed] [Google Scholar]
  • 46.Tschon M, Contartese D, Pagani S, Borsari V, Fini M. Gender and sex are key determinants in osteoarthritis not only confounding variables. A systematic review of clinical data. J CLIN MED. 2021;10(14):3178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Erb A, Brenner H, Günther K, Stürmer T. Hormone replacement therapy and patterns of osteoarthritis: baseline data from the Ulm osteoarthritis study. ANN RHEUM DIS. 2000;59(2):105–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.D’Elia HF, Larsen A, Mattsson L, Waltbrand E, Kvist G, Mellström D, Saxne T, Ohlsson C, Nordborg E, Carlsten H. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rhuematol. 2003;30(7):1456–63. [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (24.6MB, docx)

Data Availability Statement

No datasets were generated or analysed during the current study.


Articles from Arthritis Research & Therapy are provided here courtesy of BMC

RESOURCES